Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients

Therapeutic Apheresis and Dialysis

Volumn 9, Issue 4, 2005, Pages 336-339

  Koiwa, Fumihiko ^a   Kazama, Junichiro J ^b   Tokumoto, Akihide ^c   Onoda, Noritaka ^d   Kato, Hitoshi ^e   Okada, Tomoyuki ^f   Nii Kono, Tomoko ^g   Fukagawa, Masafumi ^g   Shigematsu, Takashi ^h  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c SAN IN ROSAI HOSPITAL   (Japan)

^d Sekishinkai Sayama Hospital   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f OSAKA GENERAL MEDICAL CENTER   (Japan)

^g KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h Jikei University Katsushika Medical Center   (Japan)

Author keywords

Calcium bicarbonate (CaCo3); Fibroblast growth factor 23 (FGF23); Secondary hyperparathyroidism; Sevelamer hydrochloride

Indexed keywords

CALCIUM BICARBONATE; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; SEVELAMER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; INTESTINE ABSORPTION; MALE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 29144475911     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2005.00293.x     Document Type: Article

References (16)

1. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000;277:494-8.
2. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of the vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-35.
3. White KE, Evans WE, O'Riordan JLH et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium. Nat Genet 2000;26:345-8.
4. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500-5.
5. Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-63.
6. Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002;87:4957-60.
7. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999;55:299-307.
8. Henderson J, Altmann P, Sevelamer. Nephron Clin Pract 2003;94:c53-8.
9. Manns B, Stevens L, Miskulin D et al. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 2004;66:1239-47.
10. Larsson T, Nisbeth U, Ljunggren O et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64:2272-93.
11. Imanishi Y, Inaba M, Nakatsuka K et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004;65:1943-6.
12. Nakanishi S, Kazama JJ, Nii-Kono T et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005;67:1171-8.
13. Ito M, Sakai Y, Furumoto M et al. Vitamin D and phosphate regulate fibroblast growth factor-23 in K562 cells. Am J Physiol Endocrinol Metab 2005;288:E1101-9.
14. Saito H, Maeda A, Ohtomo S et al. Circulating FGF-23 Is Regulated by 1α25-Dihydroxyvitamin D3 and Phosphorus in Vivo. J Biol Chem 2005;280:2543-9.
15. Kazama JJ, Sato F, Omori K et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005;67:1120-5.
16. Yamashita H, Yamashita T, Miyamoto M et al. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol 2004;151:55-60.